Watson Pharmaceuticals Inc, a leading specialty pharmaceutical company, received final approval from the US Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Ipratropium Bromide and Albuterol Sulfate Inhalation Solution in the 0.5 mg/3 mg strength.

Watson's Ipratropium Bromide and Albuterol Sulfate product is the generic equivalent to Dey, L.P.'s DuoNeb, which is indicated for the treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD) in patients requiring more than one bronchodilator. For the 12 months ending September 2007, DuoNeb and its generic equivalents had total US sales of approximately $265 million, according to IMS Health data. Watson intends to launch its Ipratropium Bromide and Albuterol Sulfate product immediately.

Watson Pharmaceuticals, Inc., headquartered in Corona, California, is a leading specialty pharmaceutical company that develops, manufactures, markets, sells and distributes brand and generic pharmaceutical products.